Ultrafine particle deposition in subjects with asthma. by Chalupa, David C et al.
Epidemiologic studies have shown links
between mass concentrations of ambient par-
ticulate matter and increased morbidity and
mortality in compromised individuals (Pope
et al. 2004). People with asthma appear to be
at increased risk for the adverse effects of
particulate air pollution (Frampton et al.
2000; Karol 2002; Gavett and Koren 2001).
Increased levels of particulate air pollution
are associated with asthma exacerbations,
increased respiratory symptoms, decreased
lung function, increased medication use, and
increased hospital admissions (Utell and
Frampton 2000; Devlin et al. 2000).
Particles < 100 nm (0.1 µm) in diameter
[ultraﬁne particles (UFPs)] are ubiquitous in
ambient particulate pollution and dominate
ambient particle number and surface area
concentrations, both indoors and outdoors,
because of their small size (Oberdörster et al.
1995; Frampton 2001). UFPs may contribute
to the health effects of particulate matter
because of their high surface area, oxidant
capacity, ability to evade macrophage phago-
cytosis, and propensity for inducing pul-
monary inflammation. Although few studies
have assessed the health effects of exposure to
UFPs, ambient UFP concentrations have been
associated with mortality (Wichmann et al.
2000). A panel study of subjects with asthma
(Peters et al. 1997) found that peak ﬂow varied
more closely with the 5-day mean of UFP
number than with ﬁne particle mass concen-
tration, suggesting that the UFP component of
fine particle pollution contributes to airway
effects in asthmatics. Penttinen et al. (2001)
noted that UFP number concentrations
tended to be inversely but nonsignificantly
associated with measures of lung function.
However, some epidemiologic studies have not
found associations between UFP exposure and
health effects (de Hartog et al. 2003).
Inhaled UFPs have a high predicted depo-
sition efficiency in the pulmonary region
[International Commission on Radiological
Protection (ICRP) 1994]. Thus, the expected
number of particles retained in the lung with
each breath is greater for UFPs than for larger
particles. We and others have conﬁrmed the
relatively high predicted deposition of UFPs
in healthy people breathing at rest (Anderson
et al. 1990; Brown et al. 2002; Daigle et al.
2003; Jaques and Kim 2000; Roth et al. 1994;
Schiller et al. 1988; Wilson et al. 1985). We
recently demonstrated that UFP fractional
deposition increases signiﬁcantly with breath-
ing during exercise in healthy subjects (Daigle
et al. 2003). Brown et al. (2002) observed an
increased total deposition, expressed as dose
rate, for patients with chronic obstructive lung
disease, compared with healthy subjects, with
exposure to a 33-nm (count median diameter)
ultrafine technetium-99m–labeled aerosol.
We are unaware of any previous studies meas-
uring UFP deposition in people with asthma.
Asthma is characterized by airway obstruc-
tion, with air trapping and increases in lung
residual volume. Increases in alveolar volume
would be expected to enhance diffusional depo-
sition, the primary mechanism of deposition
for UFPs, although impaired alveolar ventila-
tion would counter this increase. We hypothe-
sized that the fractional deposition of UFPs is
greater in subjects with mild asthma than in
healthy subjects without asthma, and that UFP
deposition increases further with exercise.
Materials and Methods
Subjects and experimental design. The Research
Subjects Review Board of the University of
Rochester approved the study, and informed
written consent was obtained. Subjects were
16 men and women with mild asthma who had
never smoked, were 18–55 years of age, and
were without a recent respiratory infection.
Subjects were considered to have asthma if
they had a history of repetitive symptoms char-
acteristic of intermittent bronchoconstriction
(wheezing, shortness of breath) and either
a) improvement in forced expiratory volume in
1 sec (FEV1) ≥ 12% with the administration
of inhaled albuterol if abnormally low values
were obtained for airway conductance, FEV1,
or FEV1/forced vital capacity (FVC) (Morris
et al. 1971); or b) airway hyperresponsiveness
with methacholine challenge. At the time of
screening, subjects exercised on a bicycle
ergometer for 15 min to determine the inten-
sity necessary to achieve a target minute venti-
lation of 20 L/min/m2. Subjects with FEV1
< 70% of predicted at baseline screening, or
with > 20% reduction in FEV1 after the
screening exercise, were excluded.
For the methacholine challenge, increas-
ing concentrations of methacholine (0.00,
0.08, 0.16, 0.31, 0.63, 1.25, 2.50, 5.00,
10.00 mg/mL) in normal saline were admin-
istered at 4-min intervals using a nebulizer
(model 646; Devilbiss Company, Summerset,
PA) with a dosimeter (Rosenthal-French
model D-2A; Laboratory for Applied
Immunology Inc., Fairfax, VA) calibrated to
deliver 0.01 mL/breath. Subjects were
instructed to take five breaths each lasting
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Ambient air particles in the ultraﬁne size range (diameter < 100 nm) may contribute to the health
effects of particulate matter. However, there are few data on ultraﬁne particle deposition during
spontaneous breathing, and none in people with asthma. Sixteen subjects with mild to moderate
asthma were exposed for 2 hr, by mouthpiece, to ultraﬁne carbon particles with a count median
diameter (CMD) of 23 nm and a geometric standard deviation of 1.6. Deposition was measured
during spontaneous breathing at rest (minute ventilation, 13.3 ± 2.0 L/min) and exercise (minute
ventilation, 41.9 ± 9.0 L/min). The mean ± SD fractional deposition was 0.76 ± 0.05 by particle
number and 0.69 ± 0.07 by particle mass concentration. The number deposition fraction increased
as particle size decreased, reaching 0.84 ± 0.03 for the smallest particles (midpoint CMD = 8.7 nm).
No differences between sexes were observed. The deposition fraction increased during exercise to
0.86 ± 0.04 and 0.79 ± 0.05 by particle number and mass concentration, respectively, and reached
0.93 ± 0.02 for the smallest particles. Experimental deposition data exceeded model predictions
during exercise. The deposition at rest was greater in these subjects with asthma than in previously
studied healthy subjects (0.76 ± 0.05 vs. 0.65 ± 0.10, p < 0.001). The efﬁcient respiratory deposi-
tion of ultrafine particles increases further in subjects with asthma. Key words: air pollution,
asthma, deposition, dosimetry, inhalation, ultraﬁne particles. Environ Health Perspect 112:879–882
(2004). doi:10.1289/ehp.6851 available via http://dx.doi.org/ [Online 2 March 2004]6 sec, and FEV1 was measured 30 sec after the
last breath. The concentration of methacholine
that produced a partial (20%) decrease in FEV1
(PD20) was determined by interpolation using
the regression line of the methacholine dose
response. Subjects with a PD20 > 10 mg/mL
were excluded from the study.
All exposures were by mouthpiece with a
nose clip for 2 hr, with a 10-min break off the
mouthpiece after the ﬁrst hour. In the exposure,
subjects (n = 16) were exposed to a target mass
concentration of 10 µg/m3, which corresponded
to an empirically determined number concen-
tration of 2 × 106 particles/cm3. Exposures
lasted 2 hr and included four alternating 15-min
rest and exercise (target minute ventilation,
25 L/min/m2body surface area) periods.
Exposure system. The exposures were
undertaken within an environmental chamber
in the General Clinical Research Center at the
University of Rochester Medical Center. A
mouthpiece exposure system was chosen in
order to facilitate accurate and relevant meas-
urements of respiratory deposition. Details of
particle generation and the mouthpiece expo-
sure system have been described elsewhere
(Chalupa et al. 2002; Daigle et al. 2003).
Brieﬂy, the design is a one-pass, dynamic-
ﬂow exposure system. Particles were generated
from pure graphite electrodes by spark dis-
charge in anhydrous argon, using a commercial
generator (Palas Co., Karlsruhe, Germany).
The generator settings were adjusted to provide
a nominal particle count median diameter
(CMD) of 23 nm with a geometric standard
deviation of 1.6. Particles were passed through a
charge neutralizer after generation, in order to
achieve Boltzman’s equilibrium, and were deliv-
ered continuously into diluting air in a mixing
chamber. The dilution air was passed through
charcoal and high-efﬁciency particle ﬁlters and
supplied into the mixing chamber at 120
L/min. The intake air ﬂow rate was monitored
with a Magnahelic pressure gauge (Dwyer
Instruments, Inc., Michigan City, IN), which
was calibrated using a dry test meter (Singer
American Meter Company Division, Wellesley,
MA). All tubing was electrically conductive
with lengths minimized to avoid particle loss.
Subjects wore a nose clip, inhaled through
a mouthpiece connected to the exposure sys-
tem via one-way rebreathing valves (Hans
Rudolph Inc., Kansas City, MO), and exhaled
into a dedicated exhaust line. Particles in the
reservoir entered the circuitry to the mouth-
piece according to the demands of the subject.
A resilient reservoir was placed on the expira-
tory side of the subject, loosely coupled to a
dedicated ﬁlter and exhaust system. The sys-
tem was designed to keep both sides of the
non-rebreathing valves at atmospheric pres-
sure, unaffected by the subject’s respiration.
Tubing on the expiratory side was heated to
approximately 37°C to avoid condensation.
Measurements of both inhaled and exhaled
air included particle number (condensation
particle counters, model 3220a; TSI, Inc.,
St. Paul MN) and particle size distribution
(Scanning Mobility Particle Sizer, model 3071;
TSI, Inc.). Particle mass concentration was
continuously measured on the inhaled aerosol
[tapered element oscillating microbalance
(TEOM); Rupprecht and Patachnick, Albany,
NY]. The target exposure mass concentration
was 10 µg/m3.
Electronic integration (HPChem Integrat-
ing Software, Hewlett Packard, Wilmington,
DE) of a pneumotachographic airﬂow trans-
ducer (E for M Co., White Plains, NY) on the
expiratory limb provided continuous measure-
ments of tidal volume (VT), respiratory rate,
and minute ventilation.
To determine particle losses, a reciprocal
pump was used to simulate respiration. A
resting minute ventilation of 10 L/min was
simulated using a volume of 800 mL at
12.5 cycles/min. Mild exercise (22 L/min)
was simulated using a volume of 1,200 mL at
18.3 cycles/min. Continuous upstream and
downstream measurements of particle number
and volume were determined for the whole
system and for a respiratory valve alone. Mass
losses were calculated using particle volume
determined by the electrostatic classifier.
During exercise simulation, losses were 0% for
particles ≥ 23.7 nm midpoint diameter; maxi-
mum losses were 3.9% for 7.5 nm particles.
At resting conditions, maximum losses were
13.2% for 7.5 nm particles.
UFP deposition. The total respiratory
deposition fraction (DF) was calculated for
both particle number and mass concentrations,
with correction for system losses (Chalupa et al.
2002). Inspiratory and expiratory UFP number
concentrations were measured continuously
and recorded every 5 sec during the exposure.
Particle number concentration was then aver-
aged for the periods at rest and exercise. Particle
size distribution from the inspiratory circuit was
determined before each exposure and just after
the exposure was completed. Particle size distri-
bution from the expiratory circuit was meas-
ured during one rest and one exercise period
each hour. For computational simplicity, data
on particle size distribution from the scanning
mobility particle sizer were grouped into 12 par-
ticle size bins. Four size bins each contained less
than 1% of the total expired particle number
(midpoint diameters < 8.7 and > 64.9 nm),
and these were excluded, leaving a total of
eight size bins with midpoint CMD from 8.7
to 64.9 nm (particle CMD ranging from 7.5
to 75.0 nm), which included > 98% of the
particles. The mean size-specific inspiratory
particle concentration was determined by
multiplying the average inspiratory number
concentration by the percentage of particles
in each size bin in the inspiratory circuit.
The mean size-speciﬁc expiratory particle con-
centration was determined by multiplying the
average expiratory number concentration by
the percentage of particles in each size bin in
the expiratory circuit. The correction factors
for system losses were subtracted from the
measured inspired concentrations and added to
the measured expired concentrations. The
number DF was then calculated by subtracting
the corrected expiratory number concentration
from the corrected inspiratory number con-
centration and dividing the difference by the
corrected inspiratory number concentration.
The particulate mass DF was calculated as
follows: Inspired and expired particle volume
(mass) concentrations were determined for
each size bin from the scanning mobility parti-
cle sizer data. The percentages of inspired and
expired particles by volume per bin were
determined by dividing each bin volume con-
centration by the total volume concentration
(sum of individual bins). The mean expired
mass concentration was calculated by multi-
plying the ratio of the total expired volume
concentration to the total inspired volume
concentration, times the measured (TEOM)
inspired mass concentration. The inspired
mass concentration for each bin was calculated
as the product of the inspired volume percent-
age of particles in each bin and the mean
inspired mass concentration from the TEOM.
The expired mass concentration for each bin
was the product of the expired volume per-
centage for each bin and the calculated overall
expired mass concentration. This mass data
was corrected for system losses by multiplying
each bin by the loss correction factor for that
bin and then subtracting that product from
the inspired data and adding to the expired
data. Finally, a loss-corrected DF was calcu-
lated as the loss-corrected inspired mass con-
centration minus the loss-corrected expired
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Table 1. Subject demographics and lung function.
Characteristics Mean ± SD
Age (years) 23.0 ± 2.7
M/F 8/8
Height (cm) 170 ± 8
Weight (kg) 80 ± 15
FEV1 (L/% predicted) 3.71 ± 0.91/97.6 ± 5.0
FVC (L/% predicted) 4.77 ± 1.05/106.2 ± 14.5
FEV1/FVC (%) 77.8 ± 6.9
FEF25–75 (L/% predicted) 3.32 ± 1.34/77.6 ± 29.7
DLCO (mL/min/mmHg/ 31.35 ± 7.15/99.7 ± 12.5
% predicted)
Abbreviations: DLCO, diffusing capacity for carbon
monoxide; FEF25–75, forced expiratory ﬂow rate at 25–75%
of vital capacity. 
Table 2. Breathing parameters (mean ± SD, n = 16).
Tidal Respiratory Minute
volume frequency ventilation
(L) (breaths/min) (L/min)
Rest 0.78 ± 0.14 18 ± 2.5 13.3 ± 2.0
Exercise 1.71 ± 0.46 25 ± 3.8 41.9 ± 9.0mass concentration, divided by the loss-
corrected inspired mass concentration.
The data were then compared with
theoretical total respiratory DFs calculated
using three models: a) ICRP (1994),
b) National Council on Radiological
Protection and Measurements (NCRP 1997),
and c) the Multiple Path Particle Deposition
(MPPD) model (version 1.0; Chemical
Industry Institute of Toxicology, Research
Triangle Park, NC). We found generally good
agreement among the three models, and only
the data from the MPPD predictions are
shown. This model was chosen in part because
it allowed predictions to be calculated using
each subject’s functional residual capacity,
mean respiratory frequency, and mean VT
during rest and exercise. Default values
entered for all subjects were mouth breathing,
upper respiratory tract volume 50 mL, inspira-
tory:expiratory ratio 1:2, and nominal particle
density 1.5 g/cm3. Model predictions for 23
nm particles were not affected by changes in
particle density or inspiratory:expiratory ratio.
Data means were compared using the
two-tailed Student’s t-test (Brown 1980),
with p < 0.05 denoting signiﬁcance.
Results
The sex, mean age, and spirometric values of
the subjects are shown in Table 1. Spirometry
was within normal limits for most subjects;
for ﬁve subjects the FEV1 was < 80% of pre-
dicted. Table 2 shows the mean VT, respira-
tory frequency, and minute ventilation during
the exposures, at rest, and during exercise.
The particle size distributions for the
inhaled and exhaled aerosols were nearly iden-
tical, indicating little particle agglomeration
or hygroscopic growth. Technical difﬁculties
precluded the measurement of the number
DF at rest in one subject, and the mass DF
during exercise in another subject. Table 3
lists the DF for each particle size bin at rest
and during exercise, as well as the total parti-
cle DF by number and mass. The total respi-
ratory number deposition was high at 0.76
and increased further to 0.86 with exercise.
The DF increased with exercise in all size bins.
The number DF for the smallest particles in
the size distribution (< ~15 nm) was > 0.9. No
signiﬁcant sex differences were found.
Figure 1 compares these experimental data
with predicted deposition according to the
MPPD model. Overall, the model predicted
little increase in DF with exercise, and the
experimental data exceeded model predictions
during exercise (Figure 1B).
Table 4 and Figure 2 provide comparisons
of particle deposition in the present study with
our previous ﬁndings in healthy subjects. The
number DF during breathing at rest was signif-
icantly increased in subjects with asthma com-
pared with healthy subjects. Deposition was
similar in healthy and asthmatic subjects dur-
ing exercise. In both healthy and asthmatic
subjects, exercise produced an approximate
4-fold increase in particle deposition rate, as a
consequence of both increased minute ventila-
tion and DF. The calculated total number
(and mass) of deposited particles during the
2-hr exposures was 74% (and 80%) higher
during rest, and 43% (and 47%) higher dur-
ing exercise, for the asthmatic subjects than for
the healthy subjects. This was the result of
both the higher DF and increased minute ven-
tilation in the asthmatic subjects. When both
the healthy subjects from Daigle et al. (2003),
and the present subjects with asthma were
considered together, there was no signiﬁcant
relationship between FEV1 and the DF of
UFPs (Figure 3). However, the DF increased
with increases in VT (Figure 4).
Discussion
The dose of particles that reaches the lung is a
determinant of the pulmonary response to
Article | Ultrafine particle deposition in asthma
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Table 3. Particle number DF by particle size (n = 15).
Midpoint diameter [range (nm)] DF at rest (mean ± SD) DF during exercise (mean ± SD)
8.7 (7.5–10.0) 0.84 ± 0.03 0.93 ± 0.02
11.6 (10.0–13.3) 0.83 ± 0.04 0.91 ± 0.03
15.4 (13.3–17.8) 0.80 ± 0.05 0.89 ± 0.03
20.5 (17.8–23.7) 0.77 ± 0.06 0.86 ± 0.04
27.4 (23.7–31.6) 0.72 ± 0.07 0.82 ± 0.05
36.5 (31.6–42.2) 0.68 ± 0.08 0.77 ± 0.06
48.7 (42.2–56.2) 0.66 ± 0.08 0.75 ± 0.06
64.9 (56.2–75.0) 0.65 ± 0.09 0.73 ± 0.07
Total DF by particle number 0.76 ± 0.05 0.86 ± 0.04
Total DF by particle mass 0.69 ± 0.07 0.79 ± 0.06
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Figure 1. Observed and predicted total respiratory deposition of UFPs: (A) rest; (B) exercise. Particle depo-
sition was calculated separately for eight particle size bins. Circles represent experimental data (n = 15,
mean ± SD); the solid line represents predicted deposition for these subjects at rest using the MPPD
model. Error bars indicate SD.
Table 4. Fractional and total particle deposition in healthy and asthmatic subjects exposed to carbon UFPs
for 2 hr (mean ± SD).
No. DF Mass DF Total no. deposited (× 1012) Total mass deposited (µg)
Healthy
Rest 0.65 ± 0.10 (n = 19) 0.59 ± 0.10 (n = 19) 0.70 ± 0.17 (n = 16) 3.24 ± 0.96 (n = 16)
Exercise 0.83 ± 0.04 (n = 7) 0.77 ± 0.06 (n = 7) 3.35 ± 0.90 (n = 4) 15.31 ± 0.84 (n = 4)
Asthma
Rest 0.76 ± 0.05 (n = 15) 0.69 ± 0.07 (n = 15) 1.22 ± 0.23 (n = 15) 5.83 ± 2.37 (n = 15)
Exercise 0.86 ± 0.04 (n = 15) 0.79 ± 0.06 (n = 15) 4.79 ± 1.19 (n = 15) 22.56 ± 8.96 (n = 15)
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Figure 2. Particle number DF at rest and exercise in
healthy and asthmatic subjects. Healthy subjects
are from study by Daigle et al. (2003); blue bars are
the 15 subjects with asthma from the present study.
Data represent mean ± SEM.
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Figure 3. Relationship between number DF and base-
line FEV1. Subjects with asthma are from present
study; healthy subjects are from study by Daigle et al.
(2003). Correlation coefﬁcient (R) = 0.06, p= 0.75.inhalation. If the lung dose of UFPs is higher
for people with asthma than for healthy peo-
ple given the same exposure, the risk for
health effects may also be increased. Thus,
determining particle deposition is important
in understanding susceptibility.
These studies conﬁrm our previous obser-
vation of high total respiratory deposition of
UFPs in humans (Daigle et al. 2003) and
indicate that subjects with asthma, when
breathing on a mouthpiece, have increased
UFP fractional deposition compared with
healthy subjects. Previous studies (Anderson
et al. 1990; Bennett et al. 1997; Brown et al.
2002; Svartengren et al. 1991) have shown
that patients with chronic obstructive lung dis-
ease have enhanced deposition of ﬁne particles
and UFPs. Fine particle deposition is increased
in people with asthma. For example, Kim and
Kang (1997) studied healthy and asthmatic sub-
jects inhaling an aerosol of 1 µm sebacate parti-
cles. Fractional deposition was 0.14 ± 0.02 and
0.22 ± 0.02 for the healthy and asthmatic sub-
jects, respectively, and the DF correlated
inversely with the severity of airway obstruction.
The present study is the ﬁrst effort to measure
UFP deposition in subjects with asthma.
In our previous study of healthy subjects
(Daigle et al. 2003), UFP deposition increased
significantly with exercise, exceeding model
predictions. In the present study, deposition
also increased with exercise in the subjects with
asthma, but the increase was of a smaller mag-
nitude and was not statistically signiﬁcant, per-
haps because possible factors that increase UFP
deposition during exercise, such as increased
alveolar volume and airway turbulence, are
already present in the asthmatic lung at rest.
Patients with obstructive lung disease have a
higher minute ventilation than do healthy peo-
ple, because of increased dead-space ventilation
(Tobin et al. 1983). In comparison with our
previous study of healthy individuals, during
breathing on the mouthpiece at rest, the
breathing frequency was 10% higher (17.8 vs.
16.0 breaths/min), and VT was 25% higher
(564 vs. 749 mL), giving a minute ventilation
for asthmatics that was 32% higher (9.0 vs.
13.3 L/min). We speculate that the increased
minute ventilation and hyperinflation that
are characteristic of even mild asthma enhance
diffusional deposition of UFPs in the distal
airways and alveoli.
We did not ﬁnd a signiﬁcant relationship
between FEV1 and DF (Figure 3), perhaps
partly because this study was limited to sub-
jects with mild airway obstruction, and FEV1
was > 70% of predicted for all subjects. It is
also possible that the degree of airway obstruc-
tion is a less important determinant of UFP
deposition than of fine particle deposition,
where impaction and sedimentation play more
important roles. Additional studies are needed
in people with asthma with greater impair-
ment in lung function to determine this
relationship. We did observe a signiﬁcant cor-
relation between VT and DF. Indeed,
increases in VT would be expected to increase
diffusional deposition because of longer resi-
dence time for particles in the distal lung; this
has been conﬁrmed experimentally in subjects
inhaling UFPs under controlled breathing
conditions (Jaques and Kim 2000).
Breathing on a mouthpiece tends to alter
respiratory patterns, with larger VT and minute
ventilation than during unencumbered breath-
ing (Paek and McCool 1992). It is possible
that mouthpiece breathing induced greater
increases in VT and minute ventilation in the
subjects with asthma than in healthy subjects,
and that this contributed to the observed
increase in UFP deposition. Nasal deposition
would also be expected to contribute to the
deposition values, further increasing the total
value. The demarcation between upper respira-
tory tract and lower respiratory tract deposition
would be different but mainly in that the for-
mer is larger. Thus, the conclusions reached in
this study would be expected to apply to nasal
breathing studies as well. Further studies using
controlled breathing patterns, or face mask
exposures, in healthy and asthmatic subjects
would help to address this possibility.
These studies indicate that UFP deposi-
tion is greater in people with asthma than in
healthy people. When both the increased DF
and minute ventilation were considered, the
total number of particles retained in the lung
was 74% greater in subjects with asthma than
in healthy subjects. Thus, people with asthma
have a higher total respiratory dose of UFPs
for a given exposure, which may contribute to
their increased susceptibility to the health
effects of air pollution.
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Figure 4. Relationship between number DF and mean
tidal volume during exposure. R= 0.45, p= 0.008.